Basic knowledge of Savolitinib
Sevotinib is a potent and highly selective oral MET tyrosine kinase inhibitor that exhibits clinical activity in advanced solid tumors. Sevotinib blocks abnormal activation of the MET receptor tyrosine kinase signaling pathway caused by mutations (such as exon 14 jump mutations or other point mutations), gene amplification, or protein overexpression.
Previously, Savotinib had been approved in China and marketed under the trade name Vorissa for the treatment of non-small cell lung cancer patients with MET exon 14 skipping mutations who have progressed after systemic treatment or are unable to receive chemotherapy.
Currently, sevotinib is being developed as a monotherapy or in combination with other drugs for the treatment of various types of tumors, including lung cancer, kidney cancer, and gastric cancer.
Usage and dosage:
For patients weighing ≥ 50 kilograms, it is recommended to start with a dosage of 600mg orally once daily until disease progression or intolerable toxicity occurs.
For patients weighing less than 50 kilograms, it is recommended to start with a dosage of 400mg orally once daily until disease progression or intolerable toxicity occurs.
indication:
This product is used for locally advanced or metastatic non-small cell lung cancer in adult patients with interstitial epithelial transformation factor (MET) exon 14 mutation who have disease progression or are intolerant to standard platinum chemotherapy.
Clinical study of Savotinib:
Overall, the ORR rate evaluated by IRC reached 49.2%, meeting the predetermined primary endpoint. The median response time (TTR) is 1.4 months, which means that a response can be generated approximately 6 weeks after medication. The median duration of remission (DoR) was 8.3 months, and the disease control rate (DCR) was 93.4%.
The median progression free survival (mPFS) of the overall population was 6.9 months, and the mPFS results for subgroups were as follows: mPFS for other NSCLC patients was 7.0 months, and for PSC patients it was 5.5 months; The mPFS of both the treated and initial treatment populations is 6.9 months; The mPFS of individuals without brain metastases is 6.2 months, while that of individuals with brain metastases is 7.0 months.
The median overall survival (mOS) of the general population is 12.5 months. Based on this study, sevotinib has become the first reported mature OS data and has been approved for highly selective MET-TKI in China for locally advanced or metastatic NSCLC with MET14 exon skipping mutations.
The median OS of patients with locally advanced or metastatic NSCLC with MET14 exon skipping mutations treated with sevotinib exceeded one year, and even after including a high proportion of PSC population, sevotinib still showed survival benefits in MET14 exon skipping NSCLC patients.
